Pfeffer 2015 — ELIXA Lixisenatide CVOT

New England Journal of Medicine·December 3, 2015

Marc A. Pfeffer, ELIXA Investigators

Summary

Lixisenatide was cardiovascularly noninferior to placebo but did not significantly reduce major cardiovascular outcomes after recent acute coronary syndrome.

Study Details

Study Design

Multicenter randomized double-blind placebo-controlled cardiovascular outcomes trial

Indication

Type 2 diabetes and recent acute coronary syndrome

Intervention

Lixisenatide vs placebo added to standard care

Species

Human

Sample Size

6,068 subjects

Risk of Bias Assessment

Sponsor-funded CVOT